Delivra Health | DreamWater | LivRelief
Delivra Health Brands logo
toggle menu

0.03 - 0.00

Harvest One Announces Sale of Duncan Facility for $8.2 million, Cannabis 2.0 Licence Agreement, $1.5 Million Bridge Financing and Q3 2020 Financial Results

  • Sale of Duncan Facility and its related operations confirms Harvest One’s strategic transition to a cannabis-focused Consumer Packaged Goods (“CPG”) company
  • Duncan Facility sale streamlines Harvest One’s operating model and significantly improves its cost structure and strengthens balance sheet
  • Licence Agreement provides Harvest One with royalty stream for Cannabis 2.0 brands in Canada
  • $1.5 million bridge financing secured to fund working capital in advance of the closing of sale of Duncan Facility and its related operations

June 26, 2020 – Vancouver, British Columbia – Harvest One Cannabis Inc. ("Harvest One" or the "Company") (TSX-V: HVT; OTCQX: HRVOF) is pleased to announce, as part of the Company’s previously announced Strategic Review, it has entered into a definitive agreement (the “Acquisition Agreement”) to sell its United Greeneries’ licensed cannabis cultivation and processing businesses (the “Transaction”) located in Duncan, British Columbia (the “Duncan Facility”) to Costa Canna Production Limited Liability Partnership (“Costa LLP”) and 626875 B.C. Ltd. (together with Costa LLP, the “Purchasers”) for total cash consideration of $8.2 million. Upon closing of the Transaction, Harvest One will also effect a licence agreement with the Purchasers, which will provide Costa LLP, through its licensed subsidiary, with the right to use certain licensed intellectual property of Harvest One to produce and distribute Cannabis 2.0 products in Canada in exchange for a royalty to be paid to Harvest One and, in turn, provide Harvest One with distribution for Cannabis 2.0 products in Canada.

“The agreement to sell our Duncan Facility and its related operations represents a strategic step forward for Harvest One, further divesting from its capital intensive cultivation activities and firmly establishing ourselves as a cannabis-focused CPG company,” said Andrew Bayfield, Chief Executive Officer of Harvest One. “We will continue to focus on expanding our core brands of LivRelief™, Dream Water™ and Satipharm together with the commercialization of Cannabis 2.0 product offerings in Canada.”

Mr. Bayfield continued, “When complete, this Transaction will significantly improve the Company’s overall cost structure and will provide liquidity to strengthen our balance sheet. We are continuing to take necessary and decisive measures to streamline our operations, lower our cost structure and reduce our cash burn. I am confident we are on the right path and this Transaction serves to further reinforce the Company’s plan to become cash flow positive in fiscal 2021.”

Terms of the Acquisition Agreement

Under the terms of the Acquisition Agreement the Company will sell all of the facilities, licences and assets comprising its United Greeneries’ cannabis cultivation and processing businesses in Duncan, British Columbia, for total cash consideration of $8.2 million. The Purchasers will also issue to the Company’s subsidiary, two promissory notes representing the value of certain existing cannabis and cannabis-related item inventories, to be calculated at closing. The Transaction is subject to a number of conditions, including the receipt of certain regulatory clearances and consents and the satisfaction or waiver of all conditions of closing under the Acquisition Agreement. The Transaction is anticipated to close on or around July 30, 2020.

Harvest One will retain all intellectual property associated with its Cannabis 2.0 product portfolio including, the Company’s LivReliefTM cannabis-infused topicals currently on sale in British Columbia, Alberta, Saskatchewan, Manitoba and Ontario.

Licence Agreement

Upon closing of the Transaction, Harvest One, through its wholly-owned subsidiaries, Dream Products Inc., Delivra Corp. and United Greeneries Holdings Ltd. (the “Subsidiaries”), will effect a licence agreement (the “Licence Agreement”) with United Greeneries Ltd. (“United Greeneries”) and Costa LLP. Under the terms of the Licence Agreement, United Greeneries, which will be owned by Costa LLP upon closing of the Transaction, will license and use certain intellectual property (the “Licence”) owned by Harvest One, to produce and distribute various cannabis products including, cannabis topicals (notably Delivra’s cannabis-infused LivReliefTM topical creams currently available in five provinces across Canada), cannabis extracts (including, but not limited to, cannabis vaping products), and cannabis edibles. In consideration of the Licence, the Purchasers will pay Harvest One a royalty in an amount equal to 95% of the revenue generated in relation to the Licence, less certain marked-up costs and expenses incurred by the Purchasers.

Increased Focus on Consumer Brands

With the sale of the Duncan Facility and its related operations, the Company can enhance its focus on its leading CPG brands LivReliefTM, Dream Water™ and Satipharm while leveraging its core capabilities of product development and distribution. Harvest One will continue to accelerate the commercialization of both infused and non-infused over-the-counter consumer products while leveraging its established distribution channels in North America and Europe and seeking additional partnerships to leverage the value of its portfolio of brands.

Improved Balance Sheet and Liquidity

The sale of the Duncan Facility and operations will provide an immediate infusion of capital which will contribute to a reduction in outstanding debt load as well as result in further reductions in overhead expenses. Combined with recent improvements to the overall cost structure, this will contribute to improved cash flow capabilities for the Company.

Asset-Light Operating Model

Through the Company’s new asset-light operating model, the Company will concentrate on its core capabilities while outsourcing a significant portion of its operations, including the sourcing of raw materials and contract manufacturing. The repositioned Company will be a leaner, more efficient organization focused on the higher-margin segments of the cannabis value chain.

Bridge Financing Facility

In conjunction with the Acquisition Agreement, Harvest One has secured a $1.5 million bridge financing facility (the “Bridge Facility”) from Costa LLP which will be made available to the Company upon signing the Acquisition Agreement. It is the intention of the parties that the Bridge Facility will mature and be repaid in full upon the closing of the Transaction. The Bridge Facility is secured by general security agreements over the Company’s, and its United Greeneries subsidiaries’, assets (the “Assets”), as well as guarantees provided by the United Greeneries subsidiaries. In order to facilitate the availability of the Bridge Facility, MMJ Group Holdings Limited has agreed to subordinate its security interest in certain of the Assets, to Costa LLP. The Bridge Facility carries a commitment fee of $25,000 and, if not repaid in full upon closing of the Transaction, shall bear interest at a rate of 10% per annum.

Third Quarter Financial Results

The Company today also announced its financial and operating results for the three and nine months ended March 31, 2020.

Third Quarter Financial Highlights

  • Net revenue of $3.3 million for the three months ended March 31, 2020, representing an 88% increase over the previous quarter, and a 10% increase over the same period in 2019;
  • Adjusted earnings (loss) before interest, taxes, depreciation and amortization (“Adjusted EBITDA”)(1) of ($2.4) million compared to ($5.0) million in the previous quarter representing a 51% improvement, and a 26% improvement over the same period in 2019;
  • Reduction of cash operating expenses by $1.1 million or 22% from the previous quarter as a result of cost savings initiatives implemented; and
  • Net loss of $35.4 million, which includes the impact of $27.5 million in non-cash goodwill impairment charges and $1.5 million in non-cash inventory write-downs.

Summary of Key Financial Results

  Three months ended March 31 Nine months ended March 31
Select Financial Information 2020 2019 2020 2019
($000’s, except share and per share amounts) $ $ $ $(1)
Net revenue 3,328 3,023 9,160 8,444
Gross (loss) profit (1,030) 207 301 1,912
Expenses 5,671 5,308 18,275 15,711
Loss from operations (6,701) 5,101) 17,974) 13,799)
Net loss (35,410) 5,131) 56,995) 14,258)
Net loss per share – basic and diluted (0.16) (0.03) (0.26) (0.08)
Weighted average number of common shares 214,753,073 182,215,534 214,497,526 177,789,938
Adjusted EBITDA(1) (2,441) (1,591) 10,854) (8,866)

Financial Commentary

Net revenue showed sequential growth of 88% quarter-over-quarter mainly due to a $1.6 million increase in our cultivation division from higher recreational cannabis and bulk cannabis sales, and fewer sales discounts and return provisions following a weak second quarter due to industry-wide factors. Our consumer division remained steady with a 2% decrease quarter-over-quarter despite the economic impact of COVID-19 in the latter part of the quarter. Net loss was impacted significantly by $27.5 million in non-cash goodwill impairment charges and $1.5 million in non-cash inventory write-downs.

Adjusted EBITDA(1) loss decreased quarter-over-quarter from ($5.0) million to ($2.4) million representing a significant improvement of 51%. This increase was primarily due to increased revenues as described above and ongoing efforts to reduce expenses, including a substantial reduction in headcount, professional and consulting services, rent and travel costs resulting in overall improvements in cash operating expenses.

Outlook and Strategic Review Update

Management’s outlook for sales volumes for both the consumer and medical divisions remain promising for the remainder of fiscal 2020 and into fiscal 2021 despite industry and economic headwinds. Cannabis 2.0 sales will be reflected in our fiscal Q4 2020 results as we continue to see strong demand from both our retail and provincial partners. The Company continues to focus on reducing overhead costs and is expected to report cash cost savings in fiscal Q4 2020 results compared to the same period a year ago.

The previously announced Strategic Review remains ongoing, as the Company continues to evaluate all strategic alternatives and potential sales of additional non-essential assets including the sale of the Company’s 50.1% interest in Greenbelt Greenhouse and the Lucky Lake facility. The Company will continue to evaluate all transactions or financing alternatives available to support the growth and expansion of its CPG brands and product lines.

About Harvest One

Harvest One is a global company that develops and distributes premium health, wellness and self-care products with a market focus on sleep, pain, and anxiety. Harvest One is a uniquely positioned company in the cannabis space with a focus on infused and non-infused consumer packaged goods. Harvest One owns and operates three subsidiaries; Satipharm (medical and nutraceutical); Dream Water Global, and Delivra (consumer); as well as a controlling interest in Greenbelt Greenhouse. For more information, please visit

Non-IFRS Measures, Reconciliation and Discussion

This press release contains references to “Adjusted EBITDA”, which is a non-IFRS financial measure.

Adjusted EBITDA is a measure of the Company’s overall financial performance and is used as an alternative to earnings or net income in some circumstances. Adjusted EBITDA is essentially net income (loss) with from operations before interest, taxes, depreciation and amortization and adjusted for share-based compensation, common shares issued for services, the fair value effects of accounting for biological assets and inventories, asset impairment and write-downs and other non-cash items. This measure can be used to analyze and compare profitability among companies and industries, as it eliminates the effects of financing and capital expenditures. It is often used in valuation ratios and can be compared to enterprise value and revenue. This measure does not have any standardized meaning according to IFRS and therefore may not be comparable to similar measures presented by other companies.

There are no comparable IFRS financial measures presented in Harvest One’s financial statements. Reconciliations of the supplemental non-IFRS measures will be presented in the Company’s management’s discussion and analysis for the three and nine months ended March 31, 2020. These non-IFRS financial measures are presented because management has evaluated the financial results both including and excluding the adjusted items and believe that the non-IFRS financial measures presented provide additional perspective and insights when analyzing the core operating performance of the business. The Company believes that these supplemental measures provide information useful to shareholders and investors in understanding our performance and may assist in the evaluation of the Company’s business relative to that of its peers.

These non-IFRS financial measures should not be considered superior to, as a substitute for, or as an alternative to, and should be considered in conjunction with, the IFRS financial measures presented in the Company’s financial statements. For more information, please see “Adjusted EBITDA” and “Non-GAAP Measures” in the Company’s management’s discussion and analysis for the three and nine months ended March 31, 2020, which is available on


  1. This is a non-IFRS reporting measure. For a reconciliation of this to the nearest IFRS measure, see “Adjusted EBITDA” and “Non-GAAP Measures” in the Company’s management discussion and analysis for the three and nine months ended March 31, 2020, filed on SEDAR.

Cautionary Note Regarding Forward-Looking Statements

Certain statements contained in this press release constitute forward-looking information. These statements relate to future events or future performance about Harvest One and its business and operations, which include, among other things, statements with respect to the closing of the Transaction, the Strategic Review, its corporate strategy moving forward, any transactions arising from the Strategic Review, certain financial operating metrics and financial results, and future opportunities available for the Company. The use of any of the words "could", "intend", "expect", "believe", "will", "projected", "estimated" and similar expressions and statements relating to matters that are not historical facts are intended to identify forward-looking information and are based on the Company's current belief or assumptions as to the outcome and timing of such future events. Actual future results may differ materially. The forward-looking information contained in this press release is made as of the date hereof, and the Company is not obligated to update or revise any forward-looking information, whether as a result of new information, future events or otherwise, except as required by applicable securities laws. Because of the risks, uncertainties and assumptions contained herein, investors should not place undue reliance on forward-looking information. The foregoing statements expressly qualify any forward-looking information contained herein.

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accept responsibility for the adequacy or accuracy of this release.

Investor Relations Media and Other Enquiries:
Colin Clancy Nicholas Van Dyk
Investor Relations Vincic Advisors
1-877-915-7934  1-604-364-5752

Email Signup